- Home
- KOD vs HTH Comparison
KOD vs HTH Comparison
Compare KOD & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | HTH |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | KOD | HTH |
|---|---|---|
| Price | $98.59 | $36.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 4 |
| Target Price | ★ $116.67 | $41.00 |
| AVG Volume (30 Days) | ★ 3.1M | 354.7K |
| Earning Date | 11-12-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | N/A | ★ 51.72 |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $152,188,000.00 |
| Revenue This Year | N/A | $2.13 |
| Revenue Next Year | N/A | $2.14 |
| P/E Ratio | ★ N/A | $28.71 |
| Revenue Growth | N/A | ★ 15.52 |
| 52 Week Low | $10.94 | $30.78 |
| 52 Week High | $104.00 | $40.41 |
Technical Indicators
Market Signals| Indicator | KOD | HTH |
|---|---|---|
| Relative Strength Index (RSI) | 82.25 | 36.64 |
| Support Level | $30.17 | $36.32 |
| Resistance Level | $104.00 | $38.52 |
| Average True Range (ATR) | 8.18 | 0.68 |
| MACD | 2.87 | -0.16 |
| Stochastic Oscillator | 92.94 | 21.92 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.